In yesterday’s Wall Street session, CureVac N.V. (NASDAQ:CVAC) shares traded at $10.31, down -1.06% from the previous session.
10 analysts cover CureVac N.V. (NASDAQ:CVAC), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $21.48 and a low of $9.09, we find $14.38. Given the previous closing price of $10.42, this indicates a potential upside of 38.0 percent. CVAC stock price is now 11.01% away from the 50-day moving average and 23.40% away from the 200-day moving average. The market capitalization of the company currently stands at $2.38B.
The stock has received a hold rating from 3 analysts and a buy rating from 6. Brokers who have rated the stock have averaged $14.77 as their price target over the next twelve months.
With the price target of $13, SVB Securities recently initiated with Outperform rating for CureVac N.V. (NASDAQ: CVAC).
A total of 45.44% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CVAC stock. A new stake in CureVac N.V. shares was purchased by RA CAPITAL MANAGEMENT, L.P. during the first quarter worth $131,889,000. AVIDITY PARTNERS MANAGEMENT LP invested $38,234,000 in shares of CVAC during the first quarter. In the first quarter, CAMBER CAPITAL MANAGEMENT LP acquired a new stake in CureVac N.V. valued at approximately $13,463,000. ALYESKA INVESTMENT GROUP, L.P. acquired a new stake in CVAC for approximately $11,420,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP purchased a new stake in CVAC valued at around $1,304,000 in the second quarter. In total, there are 144 active investors with 19.90% ownership of the company’s stock.
On Monday morning CureVac N.V. (NASDAQ: CVAC) stock kicked off with the opening price of $10.42. During the past 12 months, CureVac N.V. has had a low of $5.63 and a high of $15.62. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 7.60, and a quick ratio of 7.30. The fifty day moving average price for CVAC is $9.29 and a two-hundred day moving average price translates $8.35 for the stock.
The latest earnings results from CureVac N.V. (NASDAQ: CVAC) was released for Mar, 2023. For the current quarter, analysts expect CVAC to generate $16.37M in revenue.
CureVac N.V.(CVAC) Company Profile
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
